Novo Nordisk has partnered with OpenAI to accelerate drug discovery and development using artificial intelligence, as pharmaceutical companies increasingly turn to AI to improve efficiency and outcomes. The collaboration will focus on analyzing complex biological datasets, identifying potential treatments, and shortening the timeline from early research to patient use. Shares of Novo Nordisk rose about 2.8% following the announcement.
The partnership aims to apply AI to some of the most resource-intensive stages of drug development. By leveraging advanced models, Novo Nordisk expects to uncover patterns in large datasets that would be difficult to detect using traditional methods. This could help researchers identify promising drug candidates earlier and test hypotheses more quickly. The company said the approach could ultimately lead to faster development of treatments, particularly for conditions such as obesity and diabetes, where demand remains high.
For OpenAI, the deal represents a further expansion into the life sciences sector, where AI is increasingly being used to support research, clinical trials, and operational workflows. CEO Sam Altman said the technology has the potential to transform industries by enabling new discoveries and improving health outcomes.
AI’s Growing Role in Pharma
The partnership reflects a broader industry trend. Drugmakers are exploring how AI can streamline processes that traditionally take years and cost billions of dollars. While fully AI-driven drug discovery remains an emerging field, companies are already seeing benefits in areas such as clinical trial design, patient recruitment, and data analysis.
Momentum is building across the sector. Eli Lilly recently signed a $2.75 billion deal with Insilico Medicine to commercialize AI-developed therapies globally, underscoring how major pharmaceutical players are investing heavily in AI-driven pipelines. In parallel, AstraZeneca has entered a $555 million milestone-based partnership with Algen Biotechnologies to combine AI with CRISPR gene-editing for immunology drug discovery. Together, these deals illustrate how AI is moving from experimental use into core R&D and commercialization strategies.
Competing in a High-Stakes Market
Novo Nordisk’s investment in AI comes as it faces intense competition from Eli Lilly in the fast-growing weight loss and diabetes treatment market. The company has been working to strengthen its pipeline with new therapies, including next-generation drugs and alternative formulations.
The partnership also builds on Novo Nordisk’s existing AI initiatives. The company has previously collaborated with Nvidia to leverage high-performance computing infrastructure for drug discovery, including the use of the Gefion supercomputer to develop customized AI models.
By combining its pharmaceutical expertise with OpenAI’s technology, Novo Nordisk is aiming to gain an edge in both innovation speed and treatment development. As AI adoption accelerates across the healthcare sector, such partnerships are likely to become a key differentiator in the race to bring new therapies to market.